Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Grupo Biotoscana and EISAI sign exclusive licensing agreement for four novel oncology and neurology products in Latin America

Grupo Biotoscana
Posted on: 03 Oct 17

PR Newswire

MONTEVIDEO, Uruguay and WOODCLIFF LAKE, N.J., Oct. 3, 2017

MONTEVIDEO, Uruguay and WOODCLIFF LAKE, N.J., Oct. 3, 2017 /PRNewswire/ -- GBT- Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that it has entered into an exclusive licensing agreement with Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., to commercialize HALAVEN(R) (eribulin mesylate), LENVIMA(R) (lenvatinib), FYCOMPA(R) (perampanel) and INOVELON(R) (rufinamide) throughout Latin America, including Brazil, Argentina and Mexico. However, Eisai will retain the rights to Halaven and Lenvima in Mexico, and will seek to continue to build upon the growth of its oncology business in this country.

Under the new agreement, GBT will be responsible for marketing authorizations, market access, commercialization, distribution throughout Latin America.

"We are honored to be partnering with Eisai, one of the leading research-based companies in the world, in order to help expand the usage of Halaven, Lenvima, Fycompa and Inovelon, four compounds that bring new hope for patients with debilitating diseases in Latin America," said Mariano García-Valiño, CEO of Grupo Biotoscana. "We are also excited to continue building on the success of Halaven and Lenvima in Brazil, as well as to expand the reach of Eisai's oncology and neurology products through future launches in Latin America. We believe this partnership will be key for GBT, and it reinforces our position as the partner of choice for cutting-edge medicines in Latin America."

"We are excited to collaborate with Grupo Biotoscana, a company with an extensive reach in the Latin American market," said Shaji Procida, President and COO of Eisai Inc. "This agreement will provide important therapeutic options for patients in need in a number of countries where they currently remain unavailable." 

About GBT-Grupo Biotoscana

Biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology, special treatments, immunology and inflammation and rare diseases, among others. Currently present throughout 10 Latam countries. GBT's strong portfolio combines licenses and proprietary products.  www.grupobiotoscana.com.

For information on products, go to the company´s website.

Forward-Looking Statements

This release includes forward-looking statements concerning a transaction between GBT and EISAI, including expectations regarding the applicability of predictions to the commercialization of certain products. We disclaim any obligation to update any forward-looking statement, except as required by applicable law.

GBT

Melissa Angelini
Tel.: +55 11 5090 5923
ir@grupobiotoscana.com

View original content:http://www.prnewswire.com/news-releases/grupo-biotoscana-and-eisai-sign-exclusive-licensing-agreement-for-four-novel-oncology-and-neurology-products-in-latin-america-300529876.html

SOURCE Grupo Biotoscana

PR Newswire
www.prnewswire.com

Last updated on: 03/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.